# Safety Considerations for Product Design to Minimize Medication Errors Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/safety-considerations-for-product-design-to-minimize-medication-errors-guidance-for-industry/8237a0b9-a53f-4a27-a231-874107d935de

> FDA guidance document: Safety Considerations for Product Design to Minimize Medication Errors Guidance for Industry. Issue date: April 12, 2016. Get complete insights and analysis.

---

## Details

- Title: Safety Considerations for Product Design to Minimize Medication Errors Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2016-04-12
- Last Changed: 2020-04-24
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2012-D-1005">FDA-2012-D-1005</a>

## Related Documents

- [Botanical Drug Development: Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/botanical-drug-development-guidance-for-industry/bec78068-96c3-424e-b070-7b4ecfcfc8bf)
- [Immunogenicity-Related Considerations for Low Molecular Weight Heparin Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/immunogenicity-related-considerations-for-low-molecular-weight-heparin-guidance-for-industry/3f5ab3c9-bcf6-4c53-bf06-2133ec436dd8)
- [Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-human-radiolabeled-mass-balance-studies/3a1b0e14-f87e-4c72-b198-baa24f196e9a)